Hydroxyzine
- Generic Name
- Hydroxyzine
- Brand Names
- Atarax, Vistaril
- Drug Type
- Small Molecule
- Chemical Formula
- C21H27ClN2O2
- CAS Number
- 68-88-2
- Unique Ingredient Identifier
- 30S50YM8OG
- Background
Hydroxyzine is a first-generation histamine H-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties. It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. Th...
- Indication
Hydroxyzine is indicated for the symptomatic relief of anxiety and tension associated with psychoneuroses, and as an adjunct in organic disease states in which anxiety is manifested. It is also indicated in the treatment of histamine-mediated pruritus and pruritus due to allergic conditions such as chronic urticaria.
...
- Associated Conditions
- Anxiety, Nausea and vomiting, Pruritus
- Associated Therapies
- -
Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder
- Conditions
- Interventions
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2016-11-15
- Lead Sponsor
- HealthPartners Institute
- Registration Number
- NCT01372670
- Locations
- 🇺🇸
Melrose Institute, Minneapolis, Minnesota, United States
Hydroxyzine for the Prevention of Pruritus From Spinal Morphine in Transabdominal Hysterectomy Patients
- First Posted Date
- 2010-01-25
- Last Posted Date
- 2010-03-29
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 80
- Registration Number
- NCT01055236
- Locations
- 🇹🇭
Siriraj Hospital, Bangkoknoi, Bangkok, Thailand
Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal
- Conditions
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 10
- Registration Number
- NCT00661674
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Comparative Effects of Rupatadine 10 mg, Hydroxyzine 50 mg and Placebo on Actual Driving Performance
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2006-10-20
- Lead Sponsor
- J. Uriach and Company
- Target Recruit Count
- 20
- Registration Number
- NCT00162786
- Locations
- 🇳🇱
Brain and Behaviour Institute, Maastricht, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.